Literature DB >> 7736392

Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

C Garbe1, P Büttner, J Bertz, G Burg, B d'Hoedt, H Drepper, I Guggenmoos-Holzmann, W Lechner, A Lippold, C E Orfanos.   

Abstract

BACKGROUND: Numerous investigations have examined prognostic factors for patients with primary cutaneous melanoma. However, only a few studies have been published on the definition of prognostic groups. The first aim of the present study was to determine the relative importance of different prognostic factors in a large collective study. The second aim was to define prognostic groups of patients based on combinations of prognostic factors and to define a model that allows the estimation of individual survival probability.
METHODS: Long term follow-up of 5264 patients with invasive primary cutaneous melanoma was performed from 1970 to 1988 at four German University Departments of Dermatology (Berlin-Steglitz, Münster-Hornheide, Tübingen, and Würzburg). The multivariate Cox model was used to analyze 5093 patients, and 4371 patients with complete information were included in a classification and regression tree analysis (CART).
RESULTS: Tumor thickness, sex, anatomic location, and level of invasion were highly significant prognostic factors according to the multivariate analysis (P < 0.0001). However, histologic subtype and age influenced prognosis less significantly (P < 0.05). The CART analysis resulted in 12 groups defined mainly by tumor thickness, sex, and anatomic location, which were combined into five prognostic groups. The prognostic stratification defined by the five groups was superior compared with the standard TNM model. Ten-year survival rates of the five groups ranged from 97% to 14% (P < 0.0001), and an equation was used to calculate individual survival probabilities based on the significant factors of the Cox model.
CONCLUSIONS: Consideration of all significant prognostic factors of patients with primary cutaneous melanoma investigated in the present study allows for the definition of prognostic groups with a more reliable estimation of prognosis than by previous staging systems and also enables calculation of individual survival probabilities.

Entities:  

Mesh:

Year:  1995        PMID: 7736392     DOI: 10.1002/1097-0142(19950515)75:10<2484::aid-cncr2820751014>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Reducing primary melanoma mortality.

Authors:  E C Borden
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

2.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

Review 3.  Dermatology.

Authors:  M H Lowitt; N R Lowitt
Journal:  BMJ       Date:  1995-12-16

4.  [Long-term locally-recurrent melanoma].

Authors:  A G Bach; W C Marsch; C Richter; D Lübbe; P Helmbold
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

5.  Treatment and outcomes of melanoma in acral location in Korean patients.

Authors:  Mi Ryung Roh; Jihyun Kim; Kee Yang Chung
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

6.  A framework for operational modelling of hospital resources.

Authors:  Paul R Harper
Journal:  Health Care Manag Sci       Date:  2002-08

7.  Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study.

Authors:  Yuxin Ding; Runyi Jiang; Yuhong Chen; Jing Jing; Xiaoshuang Yang; Xianjie Wu; Xiaoyang Zhang; Jiali Xu; Piaopiao Xu; Shu Chen LiuHuang; Zhongfa Lu
Journal:  BMC Cancer       Date:  2021-04-16       Impact factor: 4.638

8.  Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin.

Authors:  L O Dewhurst; J W Gee; I G Rennie; S MacNeil
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  [Epidemiologic, clinical and pathologic aspects of melanoma CHU Yalgado Ouédraogo, Ouagadougou (Burkina Faso)].

Authors:  Nina Korsaga-Somé; Nayi Zongo; Edgar Ouangré; Patrice Tapsoba; Muriel Sidnomam Ouédraogo; Léopold Ilboudo; Alban Bassolet; Maryam Sanou; Djounitana Djimtibaye; Fatou Barro-Traoré; Pascal Niamba; Adama Traoré
Journal:  Pan Afr Med J       Date:  2015-03-11

10.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Authors:  J M Karjalainen; M J Eskelinen; S Nordling; P K Lipponen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.